To investigate alterations in tumor-infiltrating immune cells after the addition of PD-1 blockade to NAC, we carried out scRNA-seq on resected tumors from six patients receiving NAPC and one patient receiving NAC who were diagnosed with resectable NSCLC (Fig. 1a, Supplementary Table 1). The gene discussed is PDCD1; the disease is neoplasm.